Urologia Journal最新文献

{"title":"Safety and efficacy of retrograde intrarenal surgery (RIRS) in pediatric patients: Insights from a single-center study.","authors":"Nadeem Bin Nusrat, Assad Ur Rehman, Shujah Muhammad, Nauman Zafar, Sarmad Imtiaz, Saud Iqbal, Saira Imtiaz","doi":"10.1177/03915603261419000","DOIUrl":"10.1177/03915603261419000","url":null,"abstract":"<p><strong>Background: </strong>Pediatric urolithiasis is increasingly managed with minimally invasive approaches. Retrograde Intrarenal Surgery (RIRS) offers a promising treatment option, though data on its outcomes in children remain limited.</p><p><strong>Objective: </strong>To evaluate the safety, efficacy, and predictors of outcomes following Retrograde Intrarenal Surgery (RIRS) in pediatric patients with renal or upper urinary tract stones.</p><p><strong>Methods: </strong>From September 2022 to August 2024, retrospective observational research was carried out at the Pakistan Kidney and Liver Institute and Research Center in Lahore. Included were pediatric patients (less than 14 years old) who had RIRS for upper tract or renal stones up to 27 mm. Demographics, stone features, surgical parameters, complications, and follow-up imaging results were among the data that were taken from electronic medical records. Statistical analysis was performed using SPSS v27; multivariate logistic regression identified predictors of postoperative complications and stone clearance.</p><p><strong>Results: </strong>A total of 24 pediatric patients underwent RIRS. Mean age was 9.0 ± 4.27 years; 18 (75.0%) were male. Stones were more often left-sided (14/24, 58.3%) and commonly located at multiple sites (11/24, 45.8%). RIRS was the primary treatment in 17 (70.8%) patients. Complete stone clearance was achieved in 17 (70.8%); access failure occurred in 4 (16.7%). Postoperative complications occurred in 5 (20.8%), including sepsis in 4 (16.7%). Anatomical abnormalities were seen in 5 (20.8%). Multivariate analysis showed anatomical abnormalities were protective against complications (<i>p</i> = 0.037), while stone size >15 mm significantly reduced clearance odds (<i>p</i> = 0.009). The predictive model for clearance was significant (<i>p</i> = 0.013, <i>R</i>² = 0.519).</p><p><strong>Conclusion: </strong>RIRS is a safe and effective treatment modality for pediatric urolithiasis, achieving high stone-free rate with minimal complications. Anatomical abnormalities may reduce risk of complications, while larger stone size negatively impacts clearance. These findings support the selective use of RIRS in children with careful preoperative evaluation to optimize outcomes.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"304-310"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized study comparing outcomes of intravesical Gemcitabine, Mitomycin C (as hyperthermic intravesical chemotherapy-HIVEC) and Bacillus-Calmette Guerin in intermediate and high-risk non-muscle invasive bladder cancer.","authors":"Shreyas Nellamkuziyil Michael, Arun Makkar, Supreeth Nagaraju, Rajeev Sood, Hemant Kumar Goel, Umesh Sharma, Anurag Singla, Shivaprasad Sahoo","doi":"10.1177/03915603251388204","DOIUrl":"10.1177/03915603251388204","url":null,"abstract":"<p><strong>Introduction: </strong>Intravesical therapy following transurethral resection of bladder tumor (TURBT) remains the standard of care for non-muscle invasive bladder cancer (NMIBC). However, the global shortage of Bacillus Calmette-Guérin (BCG) and its notable side effect profile have driven interest in alternative agents such as gemcitabine and hyperthermic intravesical chemotherapy (HIVEC), both of which have shown promising results.</p><p><strong>Materials and methods: </strong>A total of 100 consenting patients with intermediate- and high-risk NMIBC, as per EAU 2020 risk stratification, were enrolled at a single institution between January 2021 and July 2022. Patients were electronically randomized in a 2:1:1 ratio into three groups: gemcitabine (<i>n</i> = 50), HIVEC (<i>n</i> = 25), and BCG (<i>n</i> = 25). Follow-up included cystoscopy and urine cytology every 3 months. Adverse events were assessed and graded using the Modified Clavien-Dindo Classification System.</p><p><strong>Results: </strong>At 12 months, recurrence-free survival (RFS) was 94% in the gemcitabine group, 84% in the HIVEC group, and 92% in the BCG group (<i>p</i> = 0.675, intention-to-treat analysis). No cases of grade or stage progression were observed. Most recurrences (88.9%) occurred in the high-risk subgroup. Treatment-related side effects were significantly more frequent in the BCG group, while gemcitabine was the most well-tolerated during both induction and maintenance phases. The most common adverse events included lower urinary tract symptoms (LUTS), dysuria, and urinary tract infections (UTIs).</p><p><strong>Conclusion: </strong>Preliminary findings indicate that intravesical gemcitabine is non-inferior to BCG and HIVEC in terms of short-term efficacy, with a significantly better safety and tolerability profile. These results position gemcitabine as a viable alternative in the management of NMIBC. However, the study's limited sample size and short follow-up period necessitate larger, long-term studies to validate these outcomes.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"170-176"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostate health supporting by a novel nutraceutical compound with antioxidant property: Results from a pilot study.","authors":"Claudio Marino, Marco Magliocchetti, Dario Di Lieto, Erika Cione, Cristina Vocca, Tommaso Ceccato, Simone Botti, Fabrizio Palumbo, Luca Gallelli, Tommaso Cai","doi":"10.1177/03915603251408298","DOIUrl":"10.1177/03915603251408298","url":null,"abstract":"<p><p>In recent years, healthcare strategies have increasingly emphasized a holistic and comprehensive approach in patient management that extends beyond the treatment of isolated physical symptoms. In this context, the use of nutraceuticals has gained interest as a complementary approach, particularly in managing chronic conditions and age-related disorders, such as lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH). A new dietary supplement, contains a blend of bio-active compounds (Drolessano^®)-including lycopene, sulforaphane, silymarin, glutathione, escine, tryptophan, and green tea extract-has been introduced in Italian pharmacopeia as food supplements in urological and andrological diseases. Here, we aim to assess the effects of Drolessano^® on serum prostate-specific antigen (PSA) levels and urinary symptoms in individuals with BPH. Fifty-five men presenting with elevated PSA values and mild lower urinary tract symptoms (International Prostate Symptom Score [IPSS] < 7) were recruited in this pilot study. All enrolled patients underwent Drolessano^® one tablet daily for 6 months. PSA concentrations and IPSS scores were recorded at baseline (T0), at 3 months (T1), and at the end of the treatment period (T2). Data at the follow-up has been compared with those at baseline. Patients enrolled experienced a statistical significance average PSA declined from 4.8 to 3.7 ng/mL (<i>p</i> < 0.003), as well as in improvement of quality of life, tested by patient reported outcomes. The supplement was generally well tolerated, and no serious adverse effects were reported during the study period. These preliminary data suggest that Drolessano^® may offer a supportive benefit in the management of BPH, particularly with respect to reducing PSA levels and improvement quality of life. Otherwise, controlled trials with larger sample sizes are needed to substantiate these findings and to better understand the underlying mechanisms of action.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"206-211"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transitional cell carcinoma in distal urethra after previous excision of HPV related condyloma: Is there a link between human papilloma virus (HPV) and transitional cell carcinoma (TCC)?","authors":"Aldo Franco De Rose, Tommaso Saccucci, Benedetta Col, Fabrizio Gallo, Maurizio Chiaramondia, Guglielmo Mantica","doi":"10.1177/03915603251412604","DOIUrl":"10.1177/03915603251412604","url":null,"abstract":"<p><strong>Introduction: </strong>We aim to present a peculiar case of a patient we treated, who underwent surgical excision of what at first were HPV-related condylomas of the urethral meatus. The second time he underwent surgical excision of what seemed a recurrence the histology showed a low grade noninvasive papillary urothelial carcinoma.</p><p><strong>Case description: </strong>A 56-year-old man who underwent surgical excision of multiple lesions of the gland and distal urethra in April 2023; the histological examination of the neoformations in distal urethra confirmed the presence of condyloma acuminatum. He experienced a recurrence of distal urethral lesion; therefore, he underwent to a new surgical excision in September 2023 and this time the histological examination showed a transitional cell carcinoma.</p><p><strong>Conclusion: </strong>There is still no clear evidence of the link between HPV infection and TCC, however attention must be placed in order to enhance awareness on HPV infection prevention and on TCC screening for patient with other HPV infection related diseases.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"261-264"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Success and challenges of ESWL for managing distal ureteric stones of 5-15 mm size.","authors":"Navdeep Garg, Sanjeev Jaiswal, Sudeep Singh, Nachiket Vyas, Shivam Priyadarshi","doi":"10.1177/03915603251387892","DOIUrl":"10.1177/03915603251387892","url":null,"abstract":"<p><strong>Introduction: </strong>Extracorporeal shock wave lithotripsy (ESWL) is widely recognized as a safe, non-invasive treatment with minimal side effects. This procedure does not require anesthesia, making it an effective option for lower ureteral stones. This study aimed to assess the effectiveness of ESWL in treating distal ureteral stones ranging from 5 to 15 mm in size and to identify factors influencing the treatment outcomes.</p><p><strong>Methodology: </strong>This was a prospective hospital-based analytical cross-sectional study conducted in the Department of Urology, tertiary care facility, Jaipur. Data collection for the study was started in September 2023 and completed in November 2024. A total of sixty one patients diagnosed with distal ureteral stones and undergoing ESWL treatments were enrolled in this study. The data was analyzed using SPSS 25.0 version.</p><p><strong>Results: </strong>The average age of the participants was 49.52 ± 10.99 years, with approximately two-thirds being male. The mean stone size was 9.93 ± 2.95 mm, and the average stone density was 765.10 ± 205.88 HU. The overall success rate of the procedure was 85.2% (<i>n</i> = 52/61). Treatment success was significantly associated with age, stone size, and BMI (<i>p</i> < 0.05), but not with the patient's sex or stone laterality (<i>p</i> > 0.05). In the multivariate analysis, the patient's BMI was identified as the only significant predictor of treatment success.</p><p><strong>Conclusion: </strong>ESWL is a successful, non-invasive, and practical therapeutic option for lower ureteric calculi with no significant side effects. It is an effective procedure for small size ureteric calculi up to 15 mm size, ESWL could therefore be used as the main form of treatment.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"235-240"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145483047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-session bilateral supine percutaneous nephrolithotomy: Safety and efficacy.","authors":"Mahmoud F Rohiem, Ahmed H Gabr, Mostafa Magdi Ali, Mohamed Nafie, Ahmed M Fawzy, Nesreen F Ibrahim, Ahmed Issam Ali","doi":"10.1177/03915603251398256","DOIUrl":"10.1177/03915603251398256","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the safety and efficacy of single-session supine bilateral percutaneous nephrolithotomy (BPCNL) in patients with bilateral renal stones.</p><p><strong>Methods: </strong>We retrospectively identified patients from February 2019 to July 2023 with bilateral renal stones measuring >2 cm and <5 cm in their maximum dimension for each side mainly located in the renal pelvis that had been treated with single-session supine BPCNL. The stone-free rate was accepted when remaining fragments of ⩽ 2 mm were discovered by a computed tomography scan.</p><p><strong>Results: </strong>Fifty-two patients with bilateral renal stones measuring 2:5 cm in their maximum dimension for each side who had been treated with single-session supine BPCNL were included in the study; a statistically significant difference in serum creatinine level was detected on day 1 postoperatively (<i>p</i> < 0.0001) compared with the baseline values that became insignificant at 1 week and 1 month postoperatively (<i>p</i> = 0.403 and 0.471 respectively). Also, statistically significant difference in glomerular filtration rate was detected at day 1 postoperatively (<i>p</i> < 0.0001) compared with the baseline values that became insignificant at 1 week and 1 month postoperatively (<i>p</i> = 0.95 and 0.07 respectively implicating early renal affection that shortly returned to normal values. The mean operative time for both sides was 126.5 ± 22.9 min, and the mean hemoglobin drop after the procedure was 1.9 ± 0.99 g/dl. The primary stone-free rate was 75%, with 11.6% of the remaining patients had a residual insignificant stones >2 mm but still less than 6 mm. Finally, 13.4% of the patients needed ancillary procedures.</p><p><strong>Conclusion: </strong>Single-session supine bilateral PCNL is both safe and effective for patients with bilateral renal stones. However, this is a complex procedure that should only be performed by expert surgeons in a tertiary centers.</p><p><strong>Trial registration number: </strong>(167) SPS/URS_008 retrospectively registered.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"249-255"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145669957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct head-to-head comparison between neoadjuvant and adjuvant chemotherapy in upper tract urothelial carcinoma: A systematic review and meta-analysis.","authors":"Naufal Naushad, Pragnitha Chitteti, Sami A Abbas, Wael Asaad, Ankur Mukherjee, Ahmed Warda, Hosam Serag, Abdalla Ali Deb","doi":"10.1177/03915603251397722","DOIUrl":"10.1177/03915603251397722","url":null,"abstract":"<p><p>The optimal timing of perioperative chemotherapy in upper tract urothelial carcinoma (UTUC) remains debated. We conducted a meta-analysis to compare neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC) in terms of pathological and survival outcomes. A systematic search identified eligible studies directly comparing NAC and AC in UTUC patients. Five studies with 1938 patients were included. Compared with AC, NAC achieved higher rates of pathological downstaging (OR: 2.13; 95% CI: 1.21-3.76) and a lower risk of positive surgical margins (OR: 0.59; 95% CI: 0.37-0.95). In contrast, lymph node metastasis rates and overall survival were similar between the two groups. Importantly, although renal function outcomes were not directly reported, prior evidence highlights the risk of post-nephrectomy renal decline, which may limit cisplatin eligibility-underscoring the rationale for NAC. Overall, NAC provides superior pathological benefits while maintaining comparable survival outcomes, supporting its consideration in eligible patients. Given the risk of post-surgical renal function decline, NAC should be considered in eligible patients to ensure timely delivery of cisplatin-based regimens. Future studies should incorporate renal functional outcomes to guide treatment selection.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"143-153"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the accuracy and reliability of overactive bladder-related YouTube videos: A digital health quality analysis using DISCERN and GQS tools.","authors":"Basri Cakiroglu, Ali Egemen Avci","doi":"10.1177/03915603261418195","DOIUrl":"10.1177/03915603261418195","url":null,"abstract":"<p><strong>Background: </strong>Overactive bladder (OAB) is a prevalent condition, and patients increasingly turn to online platforms such as YouTube for information, raising concerns about accuracy and reliability.</p><p><strong>Purpose: </strong>This study aimed to evaluate the quality and reliability of YouTube videos related to overactive bladder (OAB) using two validated instruments: the DISCERN tool and the Global Quality Scale (GQS).</p><p><strong>Methods: </strong>A systematic and structured YouTube search strategy, adapted from systematic review methodology but tailored for digital platforms, was conducted using the keyword overactive bladder. The first 100 videos retrieved were screened, and 60 met the inclusion criteria: English language, duration of at least 60 s, and relevant educational content. Exclusion criteria included non-English language, duplicates, advertisements, and purely promotional material. Two independent urologists evaluated each video using the DISCERN tool (range: 16-80) and GQS (range: 1-5). Additional data collected included video length, view count, uploader type, and thematic content. Descriptive statistics and correlation analyses were performed.</p><p><strong>Results: </strong>The median video duration was 5.6 min (IQR: 3.4-8.2), with a median view count of 34,200 (IQR: 12,500-89,000). The mean DISCERN and GQS scores were 45.2 ± 10.1 and 2.9 ± 0.8, respectively, indicating moderate overall quality. Videos uploaded by healthcare professionals or institutions had significantly higher DISCERN and GQS scores compared to those uploaded by individuals or commercial entities (<i>p</i> < 0.001). Only 28% of videos addressed neurogenic causes of OAB, and 41% did not mention behavioral therapy. A weak but statistically significant positive correlation was observed between GQS score and view count (ρ = 0.34, <i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>YouTube contains a wide array of OAB-related videos, but their quality and reliability vary considerably. While some content is accurate and informative, significant gaps remain, particularly regarding neurogenic etiologies and behavioral management. Healthcare professionals should guide patients toward trustworthy resources and consider producing evidence-based content to improve digital health literacy.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"297-303"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of ultrasound elastography versus ultrasound guided biopsy in detection of cancer prostate.","authors":"Ali Ahmed Remah, Maha Mohamed Abdel Raouf, Ahmed Mohamed Ghandour, Shaimaa El Metwally El Diasty, Mohamed Ahmed Ateya","doi":"10.1177/03915603251387890","DOIUrl":"10.1177/03915603251387890","url":null,"abstract":"<p><strong>Introduction: </strong>Elastography, introduced in the early 1990s, is a high-performing diagnostic tool that enhances conventional B-mode ultrasonography. This study assessed the diagnostic potential of ultrasound (US) elastography for early prostate cancer, using histopathology as the reference. It aimed to evaluate elastography's ability to differentiate benign from malignant prostate lesions and measure its sensitivity and specificity.</p><p><strong>Method: </strong>From June 2020 to November 2022, 22 men with prostate lesions were enrolled in a prospective study. These patients, referred from the urology outpatient clinic, had a median prostate-specific antigen of 30.6 ng/mL and a median prostate volume of 65 mL. Strain stiffness was calculated for each lesion and subsequently compared with the corresponding histopathological diagnoses.</p><p><strong>Results: </strong>A stiffness threshold between 35 and 37 kPa demonstrated the optimal discriminatory capacity between benign and malignant lesions, yielding a sensitivity of 83.3%, a specificity of 70%, a positive predictive value of 76.9%, a negative predictive value of 77.7%, and an overall accuracy of 77.2%.</p><p><strong>Conclusion: </strong>Elastography is an effective diagnostic tool that enhances B-mode ultrasound specificity for prostate cancer detection. It improves differentiation between benign and malignant lesions and increases the accuracy of prostate biopsy outcomes.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"177-184"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145490344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty-four months failure rate and functional outcomes comparison after implantable nitinol device (iTIND) and prostatic urethral lift (Urolift): real world multicenter study.","authors":"Alberto Olivero, Sabrina De Cillis, Daniele Amparore, Sofia Giudici, Carlo Buratto, Valerio Cellini, Alberto Piana, Federico Piramide, Alberto Quarà, Cristian Fiori, Erika Palagonia, Paolo Dell'Oglio, Stefano Tappero, Aldo Massimo Bocciardi, Alberto Caviglia, Antonio Galfano, Bhaskar K Somani, Amelia Pietropaolo, Francesco Porpiglia, Silvia Secco","doi":"10.1177/03915603251406809","DOIUrl":"10.1177/03915603251406809","url":null,"abstract":"<p><strong>Background: </strong>In recent years, there has been a growing trend toward minimally-invasive techniques (MISTs) in men presenting symptomatic lower urinary tract symptoms (LUTS). However, direct comparisons between techniques are rare. This work compares 2-year functional outcomes and failure rates after implantable nitinol device (iTIND) and prostatic Urethral lift (Urolift).</p><p><strong>Methods: </strong>Data of patients presenting with LUTS with an International Prostatic Symptom Score (IPSS) ⩾10, <i>Q</i>max < 12 mL/s, and prostate volume < 70 mL were obtained retrospectively from two different referral centers' databases. Patients with neurogenic bladder, sphincter abnormalities, urethral strictures, post-void residual (PVR) volume > 250 mL, urinary bladder stones, and active urinary tract infections were excluded from the study. Treatment failure was defined as the need for surgical retreatment for LUTS or ejaculatory dysfunction. Postoperative uroflowmetry, PVR, IPSS, ejaculatory function, and retreatment rate were collected at 24 months follow-up.</p><p><strong>Results: </strong>A total of 134 cases were collected. iTIND was used in 92 (68.7%) patients and Urolift in 42 (31.3%). Baseline characteristics were similar in both groups; however, Urolift patients were younger, with more significant prostate volumes and median lobe enlargement. No patients developed ejaculatory dysfunctions after the treatment, and the retreatment rate was similar in the two groups (13% vs 11.9% <i>p</i> = 0.8). Urolift demonstrated a shorter length of stay. Uroflowmetry, PVR volume, and symptom scores improved in both groups; iTIND cases showed significantly better symptom score reduction.</p><p><strong>Conclusions: </strong>The 24-month failure rate was similar for iTIND and Urolift. Urolift reported a shorter hospitalization. Uroflowmetry and PVR results were comparable in both groups. iTIND cases showed slightly superior improvements in symptom scores; however, the clinical significance of this finding must be confirmed by further studies in correlation with prostate volume and median lobe shape.</p>","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"200-205"},"PeriodicalIF":0.7,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145844199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}